glp-1 gip mechanism of action Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Figure 2 from Two incretin

Wegovy EPAR public assessment report

New research is also giving us a clearer understanding of how GLP-1s could affect cardiovascular outcomes in specific populations, such as those with known heart disease or certain types of heart failure

Importantly, efpeglenatides immunogenicity remained relatively low, with few patients developing clinically significant anti-drug antibodies, allowing its safety profile to be viewed as manageable within class expectations

With so little direct research, clinical guidelines often lean on what we can reasonably assume from the medication design and its composition, like its size, how the body absorbs it, and how likely it is to pass into breast milk, instead of real-world studies in breastfeeding mothers and babies